Physicians' Academy for Cardiovascular Education

AHA 2022

PACE-CME.org reports on news from the AHA Scientific Sessions 2022. Find coverage of the latest CV news on PACE-CME.

Long-term efficacy and safety of intravenous iron in HF

3' education - Nov. 21, 2022 - Paul R. Kalra
Paul Kalra shares the results of the IRONMAN study that investigated the effects of ferric derisomaltose on cardiovascular events in patients with iron deficiency and HF.

AHA 2022 Paul Kalra shares the results of the IRONMAN study that investigated the effects of ferric derisomaltose on cardiovascular events in patients with iron deficiency and HF.

Initial invasive vs. conservative strategy in chronic coronary disease

Literature - Nov. 14, 2022

AHA 2022 The ISCHEMIA-EXTEND study showed that after a median follow-up of 5.7 years an initial invasive strategy compared with an initial conservative strategy in patients with chronic coronary disease resulted in no difference in all-cause mortality, lower risk of CV mortality, and higher risk of non-CV mortality.

Sustained LDL-c lowering with PCSK9 siRNA up to 4 years

News - Nov. 10, 2022

AHA 2022 High CV risk patients in ORION-1 were invited to participate in open-label extension study with inclisiran -the ORION-3 study. What is the 4-year long-term efficacy and safety of inclisiran in these patients?

Dual endothelin A and B receptor antagonist reduces office SBP in resistant hypertension

News - Nov. 9, 2022

AHA 2022 The endothelin pathway may present a new target to reduce blood pressure in patients with resistant hypertension. In the PRECISION trial, BP lowering effects of aprocitentan, a dual endothelin A and B receptor antagonist, were investigated.

siRNA therapy reduces Lp(a) in patients with established ASCVD

News - Nov. 9, 2022

AHA 2022 The phase 2 OCEAN(a)-DOSE study showed that olpasiran dosed 75 mg or higher every 12 weeks reduces Lp(a) by >95% in patients with elevated Lp(a) and established ASCVD.

Expansion of trial with RDN in patients on hypertensive medication

News - Nov. 8, 2022

AHA 2022 The SPYRAL HTN-ON MED pilot trial was expanded resulting in a larger cohort of patients on hypertensive medication who underwent radiofrequency renal denervation (RDN) or sham treatment. What was the change in systolic ABPM after 6 months between the two groups?

Longer-term safety and efficacy results with cardiac myosin inhibitor in obstructive HCM

News - Nov. 8, 2022

AHA 2022 In patients with highly symptomatic obstructive HCM who were referred for septal reduction therapy (SRT), mavacamten reduced the need for SRT at 32 weeks.

Improved outcomes with rapid uptitration of HF medication after acute HF

3' education - Nov. 8, 2022 - Prof. Alexandre Mebazaa, MD, PhD
Prof. Mebazaa explains why patients and healthcare providers will love the STRONG-HF regimen of quick uptitration of HF therapies in hospitalized acute HF patients ready for discharge.

AHA 2022 Prof. Mebazaa explains why patients and healthcare providers will love the STRONG-HF regimen of quick uptitration of HF therapies in hospitalized acute HF patients ready for discharge.

Rapid uptitration of HF medication with close follow-up benefits hospitalized AHF patients

News - Nov. 8, 2022

In hospitalized acute HF patients ready for discharge, rapid uptitration of medication with close follow-up was safe and led to fewer HF hospital readmissions or deaths compared with usual care.

Low-dose statin lowers LDL-c more than dietary supplements

3' education - Nov. 8, 2022 - Luke J. Laffin, MD
**AHA 2022** An RCT showed that low-dose statin is superior in lowering LDL-c compared with placebo and 6 different dietary supplements. Moreover, dietary supplements did not significantly reduce LDL-c compared with placebo.

AHA 2022 An RCT showed that low-dose statin is superior in lowering LDL-c compared with placebo and 6 different dietary supplements. Moreover, dietary supplements did not significantly reduce LDL-c compared with placebo.

Effects of purified EPA on CV events in patients with CAD on statin therapy

News - Nov. 7, 2022

AHA 2022 The RESPECT-EPA study evaluated the effects of highly purified EPA in combination with statin therapy on CV events in Japanese patients with chronic CAD.

Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD

3' education - Nov. 7, 2022 - Prof. Pamela Douglas, MD

AHA 2022 "We feel that a precision pathway -consisting of deferred testing by quantitative analysis and CCTA with selective FFR- is a preferred strategy in stable patients with suspected CAD", says Prof. Douglas.